» Articles » PMID: 38184727

Prevalence and Influential Factors of Isolated Hepatitis B Core Antibody Positivity in a Chinese Adult Population

Overview
Journal Sci Rep
Specialty Science
Date 2024 Jan 6
PMID 38184727
Authors
Affiliations
Soon will be listed here.
Abstract

Isolated anti-HBc (IAHBc) is defined by the presence of anti-HBc in the absence of HBsAg and hepatitis B surface antibody (anti-HBs). IAHBc is of great clinical significance as a specific pattern of HBV infection, but IAHBc has not been fully clarified. This study aimed to explore the prevalence and influential factors of IAHBc from routine examination results of inpatients.A total of 61,247 individuals were included in the study, with a median age of 55 years (range: 43-68), and a male-to-female ratio of 0.90:1. The prevalence of current HBV infection (HBsAg positive) was 6.82%, while the prevalence of previous HBV infection (HBsAg negative but anti-HBc positive) was 48.63%. The prevalence of IAHBc was 12.31%. Among them, the rates for males were 7.10%, 52.16%, and 13.70%, respectively, which were significantly higher than the rates for females at 6.56%, 45.45%, and 11.06% (P < 0.05). The prevalence rates mentioned above were significantly reduced after vaccination (P < 0.05). The prevalence of IAHBc increases with age, rising from 0.23% in the age group of 15-29 years to 13.57% in individuals aged 80 and above. After the age of 50, the prevalence of IAHBc closely parallels the previous infection rate but shows no significant association with the current infection rate (P > 0.05). Among IAHBc individuals, approximately 33.83% tested positive for anti-HBe, and their anti-HBc absorbance values were significantly higher compared to anti-HBe negative individuals (7.08 and 5.31, P < 0.01). The prevalence of anti-HBe positivity among IAHBc individuals does not vary with changes in the previous infection rate and age (P > 0.05).

Citing Articles

The Effectiveness and Sero-Immunity of Hepatitis B Vaccination in People Who Use Drugs: A Systematic Review and Meta-Analysis.

Reynolds-Cortez V, Criado-Alvarez J, Martinez-Vizcaino V, Pascual-Morena C, Salinas-Vilca A, Sequi-Dominguez I Vaccines (Basel). 2024; 12(9).

PMID: 39340056 PMC: 11435961. DOI: 10.3390/vaccines12091026.


A critical review of diagnostic and prognostic markers of chronic hepatitis B infection.

Hudu S, Shinkafi S, Jimoh A Med Rev (2021). 2024; 4(3):225-234.

PMID: 38919396 PMC: 11195425. DOI: 10.1515/mr-2024-0022.

References
1.
Cao G, Jing W, Liu J, Liu M . Countdown on hepatitis B elimination by 2030: the global burden of liver disease related to hepatitis B and association with socioeconomic status. Hepatol Int. 2022; 16(6):1282-1296. DOI: 10.1007/s12072-022-10410-y. View

2.
Wang F, Zheng H, Miao N, Sun X, Zhang G, Liang X . [Analysis on sero-epidemiological characteristics of hepatitis B virus among people born during 1994-2001 before and after hepatitis B vaccine catch-up vaccination, China]. Zhonghua Yu Fang Yi Xue Za Zhi. 2017; 51(6):469-474. DOI: 10.3760/cma.j.issn.0253-9624.2017.06.003. View

3.
El-Zaatari M, Kazma H, Naboulsi-Majzoub M, Haidar M, Ramlawi F, Mahfoud Z . Hepatitis B virus DNA in serum of 'anti-HBc only'-positive healthy Lebanese blood donors: significance and possible implications. J Hosp Infect. 2007; 66(3):278-82. DOI: 10.1016/j.jhin.2007.04.010. View

4.
de Almeida Ponde R . Dynamic profile of the HBeAg-anti-HBe system in acute and chronic hepatitis B virus infection: A clinical-laboratory approach. Mol Biol Rep. 2020; 48(1):843-854. DOI: 10.1007/s11033-020-06056-4. View

5.
Launay O, Masurel J, Servant-Delmas A, Basse-Guerineau A, Meritet J, Laperche S . High levels of serum hepatitis B virus DNA in patients with 'anti-HBc alone': role of HBsAg mutants. J Viral Hepat. 2011; 18(10):721-9. DOI: 10.1111/j.1365-2893.2011.01482.x. View